Cargando…

Asenapine effects in animal models of psychosis and cognitive function

RATIONALE: Asenapine, a novel psychopharmacologic agent in the development for schizophrenia and bipolar disorder, has high affinity for serotonergic, α-adrenergic, and dopaminergic receptors, suggesting potential for antipsychotic and cognitive-enhancing properties. OBJECTIVES: The effects of asena...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marston, Hugh M., Young, Jared W., Martin, Frederic D. C., Serpa, Kevin A., Moore, Christopher L., Wong, Erik H. F., Gold, Lisa, Meltzer, Leonard T., Azar, Marc R., Geyer, Mark A., Shahid, Mohammed
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755103/ https://www.ncbi.nlm.nih.gov/pubmed/19462162 http://dx.doi.org/10.1007/s00213-009-1570-z

Ejemplares similares

Supersensitivity Psychosis and Its Response to Asenapine in a Patient with Delusional Disorder
por: Rajkumar, Ravi Philip
Publicado: (2014)

Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine
por: Takao, Nagara, et al.
Publicado: (2021)

Asenapine for bipolar disorder
por: Scheidemantel, Thomas, et al.
Publicado: (2015)

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases
por: Kanahara, Nobuhisa, et al.
Publicado: (2023)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome, Leslie
Publicado: (2011)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
por: Kinoshita, Toshihiko, et al.
Publicado: (2016)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

A Review of Asenapine in the Treatment of Bipolar Disorder
por: Vieta, Eduard, et al.
Publicado: (2017)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Transdermal Asenapine in Schizophrenia: A Systematic Review
por: Carrithers, Brennan, et al.
Publicado: (2020)

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
por: Gonzalez, Jodi M, et al.
Publicado: (2011)

Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
por: Lachaine, Jean, et al.
Publicado: (2014)

Asenapine augmentation in bipolar disorders: a case series
por: Marazziti, Donatella, et al.
Publicado: (2016)

Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070)
por: Suzuki, Katsumi, et al.
Publicado: (2021)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Treating Borderline personality disorder with Asenapine : Case report
por: Aboelenien, S. K. I. M., et al.
Publicado: (2023)

Asenapine modulates nitric oxide release and calcium movements in cardiomyoblasts
por: Grossini, Elena, et al.
Publicado: (2016)

Asenapine-induced double incontinence: A rare case report
por: Singh, Gurvinder Pal, et al.
Publicado: (2014)

The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
por: Thomas, Jennifer E., et al.
Publicado: (2015)

Augmentative Asenapine in a Recurrent Manic Catatonic Patient with Partial Response to Clozapine
por: Buoli, Massimiliano, et al.
Publicado: (2013)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
por: Bishara, Delia, et al.
Publicado: (2009)

The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
por: Pompili, Maurizio, et al.
Publicado: (2011)

New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania
por: Warren, Calvert G, et al.
Publicado: (2013)

Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review
por: Stepanova, Ekaterina, et al.
Publicado: (2017)

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis
por: Lam, Max, et al.
Publicado: (2018)

Determination of asenapine in presence of its inactive metabolites in human plasma by LC-MS/MS
por: Patel, Nirav P., et al.
Publicado: (2018)

Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report
por: Ochi, Shinichiro, et al.
Publicado: (2019)

Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia
por: Ogyu, Kamiyu, et al.
Publicado: (2020)

Stability-Indicating Liquid Chromatographic Method for the Quantification of the New Antipsychotic Agent Asenapine in Bulk and in Pharmaceutical Formulation
por: Chhalotiya, Usmangani K., et al.
Publicado: (2012)

Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
por: Caresano, Chiara, et al.
Publicado: (2014)

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study
por: Matsuzaki, Haruna, et al.
Publicado: (2021)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
por: Durgam, Suresh, et al.
Publicado: (2017)

The 5-Choice Continuous Performance Test: Evidence for a Translational Test of Vigilance for Mice
por: Young, Jared W., et al.
Publicado: (2009)

Assessing the Genetic Landscape of Animal Behavior
por: York, Ryan A.
Publicado: (2018)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
por: Citrome, Leslie, et al.
Publicado: (2017)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia
por: Maitra, Arpita, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b1gdu5loa7caaor1t231f9rskh